Centre de Lutte contre le Cancer Val d'Aurelle, Montpellier, France.
Gynecol Oncol. 2010 May;117(2):276-80. doi: 10.1016/j.ygyno.2009.12.027. Epub 2010 Mar 11.
To define the recommended dose of the association of weekly irinotecan (Iri) and cisplatin (CP) with pelvic radiotherapy in Locally Advanced Cervical Cancer.
Stage IB2-IV cervix cancer patients were treated with escalating doses of Iri starting from 30 mg/m(2) and a fixed dose of CP at 20 mg/m(2), both weekly concomitantly with a 45-Gy pelvic irradiation.
Fifteen patients entered the study, 6 at level 1 (Iri 30 mg/m(2)), 3 at level 2 (Iri 40 mg/m(2)) and 6 at intermediate dose (Iri 35 mg/m(2)). Median age was 47 years (34-72), FIGO stage IB (n=1), IIB (n=7), III (n=6), IVA (n=1). The recommended dose was weekly Iri 35 mg/m(2) and CP 20 mg/m(2). Dose limiting toxicities (grades 3-4) were diarrhea, abdominal pain, febrile neutropenia and fatigue.
In cervix cancer patients, radiosensitization with weekly cisplatin and irinotecan is feasible, and the recommended doses are cisplatin 20 mg/m(2)/week and irinotecan 35 mg/m(2)/week for future phase II studies.
确定每周伊立替康（Iri）联合顺铂（CP）与盆腔放疗联合用于局部晚期宫颈癌的推荐剂量。
对 IB2-IV 期宫颈癌患者进行递增剂量的 Iri 治疗，起始剂量为 30mg/m²，同时每周给予固定剂量的 CP 20mg/m²，并与 45Gy 的盆腔照射同时进行。
15 名患者入组本研究，1 名患者处于 1 级（Iri 30mg/m²），3 名患者处于 2 级（Iri 40mg/m²），6 名患者处于中间剂量（Iri 35mg/m²）。中位年龄为 47 岁（34-72 岁），FIGO 分期 IB（n=1），IIB（n=7），III（n=6），IVA（n=1）。推荐剂量为每周 Iri 35mg/m²和 CP 20mg/m²。剂量限制毒性（3-4 级）为腹泻、腹痛、发热性中性粒细胞减少和疲劳。
在宫颈癌患者中，每周顺铂和伊立替康联合放疗是可行的，未来的 II 期研究推荐剂量为每周顺铂 20mg/m²和伊立替康 35mg/m²。
